Falsified or Substandard? Assessing Price and Non-price Signals of Drug Quality

Journal of Economics and Management Strategy

Volumn 24, Issue 4, 2015, Pages 687-711

  Bate, Roger ^a   Jin, Ginger Zhe ^b,c   Mathur, Aparna ^a  

^a AMERICAN ENTERPRISE INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84945265708     PISSN: 10586407     EISSN: 15309134     Source Type: Journal    
DOI: 10.1111/jems.12114     Document Type: Article

References (36)

1. Bate, R., 2012, Phake: The Deadly World of Falsified and Substandard Medicines, American Enterprise Institute Press. Washington, D.C.
2. Bate, R. and K. Hess, 2010, "Anti-Malarial Drug Quality in Lagos and Accra-A Comparison of Various Quality Assessments, " Malaria Journal, 9, 157-163. DOI:10.1186/1475-2875-9-157.
3. Bate, R., R. Tren, and J. Urbach, 2006, Still Taxed to Death: An Analysis of Taxes and Tariffs on Medicines, Vaccines and Medical Devices, Washington, DC: AEI-Brookings Joint Center for Regulatory Studies.
4. Bate, R., P. Coticelli, R. Tren, and A. Attaran, 2008. "Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa-A six country study, " PLoS ONE, 3, e2132. DOI:10.1371/journal.pone.0002132.
5. Bate, R., R. Tren, L. Mooney, et al., 2009a, "Pilot Study of Essential Drug Quality in Two Major Cities in India, " PLoS ONE4: e6003. DOI:10.1371/journal.pone.0006003.
6. Bate, R., R. Tren, K. Hess, L. Mooney, and K. Porter, 2009b, "Pilot Study Comparing Technologies to Test for Substandard Drugs in Field Settings, " African Journal of Pharmacy and Pharmacology, 3, 165-170.
7. Bate, R., K. Hess, and L. Mooney, 2010a, "Medicine Registration and Medicine Quality: A Preliminary Analysis of Key Cities in Emerging Markets." Research and Reports in Tropical Medicine, 1, 89-93. DOI: 10.2147/RRTM.S15199.
8. Bate, R., P. Emily, S. Naoshy, A. McPherson, and L. Mooney, 2010b. "Drug Registration-A Necessary but not Sufficient Condition for Good Quality Drugs-A Preliminary Analysis of 12 Countries." Africa Fighting Malaria Working Paper, Africa Fighting Malaria.
9. Bate, R., G.Z. Jin, and A. Mathur, 2011, "Does Price Reveal Poor-Quality Drugs? Evidence from 17 Countries, " Journal of Health Economics, 30, 1150-1163.
10. Bate, R., P. Jensen, K. Hess, L. Mooney, and J. Milligan, 2013, "Substandard and Falsified Anti-Tuberculosis Drugs - A Preliminary Field Analysis." The International Journal of Tuberculosis and Lung Disease, 17, 308-311. DOI: 10.5588/ijtld.12.0355.
11. Bennett, D. and Y.Wesley, 2013, "The Market for High-Quality Medicine, " Working Paper, University of Chicago.
12. Caudron, J.M., N. Ford, M. Henkens, C. Mace, R. Kiddle-Monroe, and J. Pinel, 2008, "Substandard Medicines in Resource-Poor Settings: A Problem that Can no Longer be Ignored, " Tropical Medicine and International Health, 13, 1062-1072.
13. Cockburn, R., P.N. Newton, E.K. Agyarko, D. Akunyili, and N.J. White, 2005, "The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers, " PLoS Medicine, 2, e100.
14. Dresher, M., 1962, "A Sampling Inspection Problem in Arms Control Agreements: A Game-Theoretic Analysis, " Memorandum RM-2972-ARPA, The RAND Corporation, Santa Monica, California.
15. Fitzpatrick Christopher and Katherine Floyd, 2012, "A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug Resistant Tuberculosis, " Pharmacoeconomics, 1, 63-80.
16. Grossman, G. and C. Shapiro, 1988, "Counterfeit-Product Trade, " American Economic Review, 78, 59-75.
17. Institute of Medicine (IOM 2013). "Countering the Problem of Falsified and Substandard Drugs, " G.J. Buckley and L.O. Gostin, eds., Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Washington DC, National Academies Press. Available at http://www.nap.edu/catalog.php/record_id=18272 (July 25, 2013).
18. Jähnke, R.W.O., G. Küsters, and K. Fleischer, 2001, "Low-Cost Quality Assurance of Medicines Using the GPHF-Minilab®, " Drug Information Journal, 35, 941-945.
19. Kaale, E., P. Risha, and T. Layloff, 2011, "TLC for Pharmaceutical Analysis in Resource Limited Countries, " Journal of Chromatography A, 1218, 2732-2736.
20. Kelesidis, T., I. Kelesidis, P.I. Rafailidis ., and M.E. Falagas, 2007, "Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence, " Journal of Antimicrobial Chemotherapy, 60, 214-236.
21. Leland, H.E., 1979, "Quacks, Lemons, and Licensing: A Theory of Minimum Quality Standards, " Journal of Political Economy, 87, 1328-1346.
22. Maschler, M., 1966, "A Price Leadership Method for Solving the Inspector's Non-constant Sum Game, " Naval Research Logistics Quarterly, 13, 11-33.
23. Milgrom, P. and J. Roberts, 1986, "Price and Advertising Signals of Product Quality, " Journal of Political Economy, 94, 796-821.
24. Nayyar Gaurvika, M.L., J.G. Breman, P.N. Newton, and J. Herrington, 2012. "Poor-Quality Antimalarial Drugs in Southeast Asia and Sub-Saharan Africa, " Lancet, 12, 488-496.
25. Newton, P.N., C. Robert Agyarko, E. Kyeremateng, D. Akunyili, and N.J. White, 2005. "The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers, " PLoS Medicine. Available at: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0020100. Accessed on June 1, 2013.
26. Newton, P.N., M.D. Green, and F.M. Fernandez, 2010a, "Impact of Poor-Quality Medicines in the 'Developing' World, " Trends in Pharmacological Sciences, 31, 99-101. Available at: http://www.sciencedirect.com/science/article/pii/S016561470900203X.
27. Newton, P.N., M.D. Green, and F.M. Fernandez, 2010b "Impact of poor-quality medicines in the 'developing' world." Trends in Pharmacological Sciences, 31, 99-101. Available at: http://www.sciencedirect.com/science/article/pii/S016561470900203X. Accessed on June 1, 2013.
28. Newton, P.N., A.A. Amin, C. Bird, P. Passmore, G. Dukes, G. Tomson, B. Simons, R. Bate, P.J. Guerin, and N.J. White, 2011 "The Primacy of Public Health Considerations in Defining Poor Quality Medicines, " PLoS Medicine, 8, e1001139. DOI:10.1371/journal.pmed.1001139.
29. Oxfam, 2011, "Eye on the Ball Medicine Regulation - Not IP Enforcement - Can Best Deliver Quality Medicines, " 143 Oxfam Brief Paper.
30. Pincock, S., 2003, "WHO Tries to Tackle Problem of Counterfeit Medicines in Asia, " British Medical Journal, 327, 1126.
31. Qian, Y., 2008, "Impacts of Entry by Counterfeiters, " The Quarterly Journal of Economics, 123, 1577-1609.
32. Qian, Y., 2014, "Brand Management and Strategies Against Counterfeits, " Journal of Economics and Management Strategy, 23, 317-343.
33. USAID, (2009) "Growing Threat of Substandard and Counterfeit Medicines in Developing Countries Addressed by New USAID-USP Cooperative Agreement, " USAID press release, Available at: http://www.usaid.gov/press/releases/2009/pr091026_1.html (April 22, 2012).
34. Wolinsky, A., 1983, "Prices as Signals of Product Quality, " The Review of Economic Studies, 50, 647-658.
35. World Health Organization, 2010, "Medicines: spurious/falsely-labelled/ falsified/counterfeit (SFFC) medicines", fact sheet 275, Available at: http://www.who.int/mediacentre/factsheets/fs275/en/index.html (April 22, 2012).
36. World Health Organization, 2011, "Report of the Working Group of Member States on Substandard/Spurious/Falsely-Labelled/Falsified/Counterfeit Medical Products, " Available at: http://apps.who.int/gb/ssffc/pdf_files/A_SSFFC_WG5-en.pdf (October 11, 2012).